Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

KU-0063794

HY-50710

(KU 0063794; KU0063794)

KU-0063794

KU-0063794 Chemical Structure

KU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively); no effect on PI3Ks.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $70 In-stock
50 mg $220 In-stock
100 mg $400 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €54 In-stock
5 mg €49 In-stock
10 mg €69 In-stock
50 mg €216 In-stock
100 mg €392 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: KU-0063794
Cat. No.: HY-50710

KU-0063794 Data Sheet

  • View current batch:

    Purity: 99.79%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of KU-0063794

KU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively); no effect on PI3Ks.
IC50 value: ~10 nM [1]
Target: mTORC1/C2
KU-0063794 displays no activity at PI 3-kinase or 76 other kinases tested. Inhibits activation and hydrophobic motif phosphorylation of Akt, S6K and SGK, but not RSK. KU-0063794 suppresses cell growth and induces G1 cell cycle arrest in vitro.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 465.54 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C₂₅H₃₁N₅O₄
CAS No 938440-64-3
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.1480 mL 10.7402 mL 21.4804 mL
5 mM 0.4296 mL 2.1480 mL 4.2961 mL
10 mM 0.2148 mL 1.0740 mL 2.1480 mL

Clinical Information of KU-0063794

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
KU-0063794 Queen Mary University of London Metastatic renal cancer 28-FEB-13 31-DEC-15 Phase 2 15-NOV-13
AstraZeneca plc Advanced solid tumor 31-DEC-09 28-FEB-14 Phase 1 06-NOV-13
AstraZeneca plc Metastatic breast cancer 31-MAY-12 30-NOV-13 Phase 1 01-NOV-13

References on KU-0063794

Inhibitor Kit

Related mTOR Products

  • AP1903

    AP1903 is a homodimer binding to FKBP; elicites potent and dosedependent apoptotic death of engineered cell line HT1080 in culture with an EC50 of 0.1 nM

  • AP20187

    AP20187 is a synthetic, cell-permeable ligand that can be used to induce homodimerization of fusion proteins containing the DmrB domain.

  • AZD-8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM with excellent selectivity (~1,000-fold) against PI3K isoforms and ATM/DNA-PK.

  • AZD2014

    AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms ((alpha)/(beta)/(gamma)/(delta)).

  • CC-223

    CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K(alpha) (IC50=4 (mu)M).

  • CZ415

    CZ415 is a potent and highly selective mTOR inhibitor.

  • Deforolimus

    Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin.

  • ETP-46464

    ETP-46464 is a cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-K(alpha), and ATM (IC50= 0.6, 14, 36, 170, and 545 nM, respectively).

  • Everolimus

    Everolimus (RAD001) is a mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.

  • GDC-0084

    GDC-0084 is a potent, selective inhibitor of Class I PI3K and mTOR with good penetration across the blood-brain barrier.

MORE